TheraRadar
← Back
Data updated: Mar 29, 2026

UMEDICA

CardiovascularImmunologyNeurology
Generics

UMEDICA is a generic drug manufacturer focused on Cardiovascular, Immunology, Neurology.

2018
Since
17
Drugs
-
Trials
298
Approved (2yr)

Key Drugs

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide
Cardiovascular
AT1 receptor 1 indications · 2016

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

EFINACONAZOLE 2026-02-23
CELECOXIB 2026-02-12
Labeling
GLYCOPYRROLATE 2026-02-10
Labeling
GLYCOPYRROLATE 2026-02-06
Labeling
SERTRALINE HYDROCHLORIDE 2026-01-29
SERTRALINE HYDROCHLORIDE 2026-01-28
ATORVASTATIN CALCIUM 2026-01-22
Manufacturing (CMC)
SERTRALINE HYDROCHLORIDE 2026-01-20
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 51%
3 drugs Phase 1: 1
Immunology 32%
2 drugs
Neurology 16%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

PAI HOLDINGS PHARM big-pharma
Neurology, Cardiovascular, Immunology
Novartis big-pharma
Cardiovascular, Immunology
UPJOHN big-pharma
Neurology, Cardiovascular, Immunology
Merck big-pharma
Cardiovascular, Immunology
AbbVie big-pharma
Immunology, Neurology